01—Abstract
Summary
Summary of the 10-K filed March 3, 2000. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' 10-K for fiscal 1999 shows a company in transition from discovery-stage biotech to early commercial operations.
The first product, Agenerase (amprenavir), an HIV protease inhibitor, launched in May 1999 and generated $49.7 milliona in total sales over the last seven months of 1999, with Vertex receiving $7.5 million in royalties from Glaxo Wellcome. Total revenues rose 39% to $61.6 million from $44.4 million, but the net loss widened to $41.0 million ($1.61 per share) from $33.1 million, as R&D spending climbed to $72.2 million and SG&A to $26.1 million. Management guides to significant operating losses in 2000 and beyond, so profitability is not expected in the near term.
The balance sheet remains solid but is shrinking. Cash and investments fell to $187.8 millionb from $245.7 million, driven by $31.8 million of operating cash burn and $16.2 million of capital spending. Management says existing resources should fund operations for at least two years, supplemented by Agenerase royalties, partner payments, and a new $20 million credit line.
Partnership income is a significant part of the story: Aventis (VX-740, up to $62 millionc in milestones), Taisho (caspase inhibitors), Schering AG, Kissei, Eli Lilly, and Glaxo Wellcome all contribute research funding and milestone revenue. Key risks include a heavy reliance on partners for development and commercialization, limited marketing and manufacturing experience, competition from four other HIV protease inhibitors, an ongoing Chiron patent infringement suit, and the potential impact of SAB 101 revenue recognition rules on reported results in 2000. The stock traded between $19.38 and $82.56 over the prior twelve months, and the February 28, 2000 close was $62.00, reflecting investor enthusiasm about the pipeline and the chemogenomics platform.
02—Key points
Key Highlights
- Agenerase (amprenavir) launched in May 1999 after FDA accelerated approval; $49.7M in sales over the final seven months of 1999 and $7.5M in royalties to Vertex from Glaxo Wellcome
- Total revenues rose 39% to $61.6M (from $44.4M), led by collaborative R&D revenue of $42.5M and royalties and product sales of $8.1M
- Net loss widened to $41.0M ($1.61/share) from $33.1M ($1.31/share) as R&D expenses grew 23% to $72.2M and SG&A rose 44% to $26.1M
- Cash and investments declined to $187.8M from $245.7M; management believes this is sufficient for at least two years of operations
- Seven drug candidates in clinical development, including VX-497 (hepatitis C and psoriasis), Incel (multidrug resistance in cancer), and VX-740 (rheumatoid arthritis, partnered with Aventis)
- Broad partnership network with Glaxo Wellcome, Aventis, Schering AG, Eli Lilly, Kissei, and Taisho, with up to $62M in milestones tied to VX-740 alone
- SAB 101 adoption in Q1 2000 could materially increase reported net losses, and the Chiron patent suit remains pending
03—Questions
Frequently Asked Questions
Is Vertex profitable, and when is it expected to be?
No. Vertex has reported operating losses every year since inception, with a 1999 net loss of $41.0M. Management expects a significant operating loss in 2000 and believes losses will continue beyond 2000, even with meaningful Agenerase royalties, because it plans to keep investing heavily in R&D and commercialization.
How is Agenerase performing in the market?
Agenerase reached $49.7M in sales over its first seven months on the market and is used by more than 10,000 U.S. patients. However, it competes with four other HIV protease inhibitors, Glaxo Wellcome controls most marketing, and Vertex has limited influence over commercial outcomes. EU approval is anticipated in 2000.
Does Vertex have enough cash to fund its operations?
Vertex had $187.8M in cash and investments at year-end 1999, down $57.9M over the year, with $31.8M used in operations. Management believes this is sufficient for at least two years. It also has a $20M equipment credit line, which was undrawn at year-end, and expects future funding from Agenerase royalties and partner payments. Equity or debt raises could still be needed if these sources fall short.
What are the most significant near-term pipeline catalysts?
Key items include the Aventis Phase II trial of VX-740 in rheumatoid arthritis with a larger study planned for 2000; Glaxo Wellcome's expected Phase III start for VX-175 in 2000; a planned Phase II study of VX-497 combined with interferon-alpha in 2000; and the readout of five Incel Phase II studies expected to complete in 2000. Incel is being tested in ovarian, breast, sarcoma, prostate, and small cell lung cancers.
What legal or accounting risks should investors watch?
Vertex is defending a Chiron Corporation patent infringement suit over hepatitis C protease research, which is currently stayed pending a USPTO reexamination. Management considers the outcome unlikely to have a material impact on its financial position. Separately, SAB 101 revenue recognition guidance takes effect in Q1 2000, and management warns it could materially increase reported net losses in that quarter.
04—Continue